Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.9K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

2.7K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.7K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

14.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.9K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.1K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A surviving beta cell subpopulation enriched in patients with T1D.

bioRxiv : the preprint server for biology·2026
Same author

New and emerging therapies in type 1 diabetes mellitus.

The Journal of clinical investigation·2026
Same author

Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells in systemic lupus erythematosus and averts glomerular pathology.

bioRxiv : the preprint server for biology·2026
Same author

Tet2 modulates ER stress responses related to β-cell death and autoimmunity in diabetes.

iScience·2026
Same author

Identification of a novel TLR7 gain-of-function variant that underlies systemic lupus erythematosus.

Journal of human immunity·2026
Same author

EBV reprograms autoreactive anti-CNS B cells as antigen presenting cells in multiple sclerosis.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Mar 20, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K

Progress and challenges for treating Type 1 diabetes.

Justin W Garyu1, Eric Meffre1, Chris Cotsapas2

  • 1Department of Immunobiology, Yale University, New Haven, CT, USA.

Journal of Autoimmunity
|May 24, 2016
PubMed
Summary
This summary is machine-generated.

Over 30 years of Type 1 diabetes (T1D) research reveals genetic links and immune mechanisms causing beta cell destruction. Current therapies improve function but don't prevent insulin loss, necessitating new strategies.

Keywords:
AutoimmunityImmune therapyToleranceType 1 diabetes

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.4K
Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters
08:09

Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters

Published on: May 18, 2014

14.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.4K
Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters
08:09

Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters

Published on: May 18, 2014

14.8K

Area of Science:

  • Immunology
  • Endocrinology
  • Genetics

Background:

  • Cyclosporin A trials for new-onset Type 1 diabetes (T1D) began over 30 years ago.
  • Advances include understanding genetic predisposition, immune tolerance failures, and mechanisms of beta cell destruction.
  • Key genes (MHC, PTPN22, CTLA-4, IL-2RA) and thymic antigen presentation influence autoimmune risk.

Purpose of the Study:

  • To review developments in T1D therapeutics.
  • To identify patient characteristics benefiting most from therapies.
  • To highlight areas needing further research for more effective strategies.

Main Methods:

  • Review of scientific literature on T1D pathogenesis and immunotherapy.
  • Analysis of genetic and immunological insights.
  • Evaluation of clinical trial outcomes and therapeutic limitations.

Main Results:

  • Identified antigens recognized by the immune system in T1D patients.
  • Elucidated novel cellular mechanisms of beta cell killing, including islet antigen presentation.
  • Clinical trials show some efficacy in improving beta cell function, but none achieve permanent insulin secretion preservation.

Conclusions:

  • Heterogeneity of immune responses, therapy recurrence, and intrinsic beta cell death may limit long-term therapeutic success.
  • Further research is needed to address incomplete understanding and develop superior T1D treatment strategies.
  • Identifying patient subgroups most likely to respond to therapies is crucial.